Masterclass.

In the final instalment of this masterclass, we explore current available treatment options and the treatments that are in development in both the laboratory and clinical trial stages.

In the second instalment of this masterclass, we discuss the wide variety of types and sub-types of ovarian cancer including the variations in symptoms and survival rates.

In the first instalment of this masterclass, we discuss the signs and symptoms that indicate ovarian cancer, along with the importance of bringing these symptoms to a healthcare professional as early as possible.

In this 3rd and final blog of the series, Josh describes the current management of HIV/AIDS, discusses the medicines in development, and provides an insight into the health inequality impacting this condition.

In our previous blog, we looked at the initial discovery of HIV, the mechanisms of how it infects CD4 cells and the human cost of the virus in the 1980s. Here, we will discuss the first treatments to become available for HIV, their side effects, the stigma associated with the disease and what that meant for patient prognosis, and the introduction of Highly Active Antiretroviral Therapy (HAART).

As the third blog of the immunisation masterclass series is published on International HPV Awareness Day, Pharmora would like to take this opportunity to highlight the importance of HPV vaccination. Read this blog where we explore HPV and its associated risk, why you need an HPV vaccination, and debunk some common myths around the topic!

Continuing the Immunisation Masterclass series, our second blog revolves around the topic of oral vaccines. Read on to learn more about what oral vaccines are, what are they used for, their mechanism of action, and clinical trials of oral vaccines.

In the first blog of this Master Class series, we will discuss the basics of HIV, including some of the history of its discovery and how it links to AIDS.

On 11th September there was an EMA webinar to launch the updates to GVP Module XVI on Risk Minimisation Measures and its Addendum II. Read on for a summary of the key updates…

The Risk Management Plan (RMP) is a detailed description of the activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicines. Read on to find out how this important document differs across the world.

August was National Immunisation Awareness Month. To highlight the importance of getting vaccinated, Pharmora has prepared a Masterclass series, discussing types of vaccines, why we need them, and the health implications of getting a jab. Read this first blog to understand the current vaccination scheme in the UK, and boost your general knowledge on immunisation!

To celebrate the anniversary of the finalisation of the HGR Implementation Rules in China, we have published a series of blogs, covering the basis, history, recent changes and importance of HGR.

In this final blog of the series, we will describe the different types of licensing and explain how to save time navigating the steps involved in applying for an administrative licence for international clinical trials. Read on to learn more…

To celebrate the first anniversary of finalisation of the HGR regulations we are exploring this important regulation and how it impacts on our work.

Part two of this HGR series explains how to identify which samples could fall under this regulation, how to determine whether you are defined as a “Foreign party” and describes the recent changes to the regulatory structure overseeing HGR. Read on to learn more…

To celebrate the anniversary of finalisation of this important regulation, we have created a series of blogs, exploring the HGR regulation in China, recent changes and how it impacts our work in clinical development. Read the first in our HGR series to find out more…